Here are three things to know.
1. The FDA previously approved Imbruvica for the treatment of lymphocytic leukemia.
2. Under the expanded approval, the drug can be used to treat adult patients with chronic graft versus host disease, which occurs when immune cells from donated tissues — often stem cells from donated bone marrow — attack the new host’s body cells.
3. Imbruvica is the first FDA-approved therapy for the treatment of chronic graft versus host disease.
More articles on supply chain:
Senate passes FDA user fee reauthorization bill
6 must-reads for supply chain leaders this week
Express Scripts adds 64 drugs to exclusion list
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
